Management of incontinence-associated dermatitis patients using a skin protectant in acute care: a case series
| Autor: | Paul Bainbridge, Paul Browning, Claire Acton, Nicola Ivins |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Nursing (miscellaneous) Erythema Protective Agents 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Acute care medicine Humans Cyanoacrylates 030212 general & internal medicine Aged Skin Aged 80 and over business.industry Middle Aged Skin Care medicine.disease Dermatology Urinary Incontinence Elastomers Irritant contact dermatitis Buttocks Dermatitis Irritant Female Fundamentals and skills medicine.symptom business Fecal Incontinence |
| Zdroj: | Journal of Wound Care. 29:18-26 |
| ISSN: | 2052-2916 0969-0700 |
| DOI: | 10.12968/jowc.2020.29.1.18 |
| Popis: | Objective: Incontinence-associated dermatitis (IAD) is a common type of irritant contact dermatitis. It is categorised by persistent erythema and can be associated with denudation and/or colonisation and infection. IAD is challenging to treat and affects 3.4–50% of patients. This case series evaluates a novel, elastomeric, advanced skin protectant (3M Cavilon Advanced Skin Protectant) in a UK acute health-care setting, for the management of IAD in patients suffering from moisture-associated skin damage (MASD) in the sacral/genital area. Method: The patient's skin was assessed by clinicians using the GLOBIAD classification tool at the point of recruitment and to monitor progress throughout the study period. The product was applied as a single layer in accordance with the instructions for use. Patients, when able, were asked to assess their own pain level using the Wong-Baker FACES pain scale. Photographs were taken as part of the ongoing assessment. Results: The skin protectant was used on average every 2.28 days. Of the 18 IAD patients recruited, 79% (n=11) were classified as IAD-free, based on the GLOBIAD categorisation tool, by the end of the evaluation period. Skin deterioration during the evaluation period was seen in one patient (6%), and of the patients able to complete pain assessments, 55% (n=6) reported a reduction in pain. Conclusion: These results suggest that the elastomeric skin protectant, applied every three days, plays a role in the improvement of IAD. The skin protectant adheres to wet and weeping partial-thickness wounds and may aid IAD management. Reducing application to every third day supports a change in practice which may offer benefits to patients and caregivers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|